# ChromaDex Corporation (CDXC)

Source: https://www.quantisnow.com/company/CDXC
Generated: 2026-11-11T12:57:02.839Z

- Ticker: CDXC
- Exchange: NASDAQ
- Sector: Health Care
- Industry:  Medicinal Chemicals and Botanical Products 
- Website: chromadex.com

## About

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

## Latest CDXC news and filings

- 2025-03-19 12:32 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-amendments-to-articles-of-5951724)
- 2025-03-13 12:34 UTC [ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025](https://www.quantisnow.com/insight/chromadex-corp-announces-name-change-to-niagen-bioscience-inc-and-5942421)
- 2025-03-11 20:04 UTC [Conference Announcement] [ChromaDex to Present at the 37th Annual Roth Conference](https://www.quantisnow.com/insight/chromadex-to-present-at-the-37th-annual-roth-conference-5938078)
- 2025-03-10 12:11 UTC [Insider Buy] [SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)](https://www.quantisnow.com/insight/svp-general-counsel-lopez-carlos-luis-bought-2146-worth-of-5935040)
- 2025-03-04 21:02 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-results-of-operations-and-5923219)
- 2025-03-04 21:02 UTC [Earnings Date] [ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results](https://www.quantisnow.com/insight/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2024-results-5923203)
- 2025-03-04 21:01 UTC [SEC Form 10-K] [SEC Form 10-K filed by ChromaDex Corporation](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-chromadex-corporation-5923190)
- 2025-02-27 21:42 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Fried Robert N](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-fried-robert-5915099)
- 2025-02-27 21:29 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-leadership-update-financial-statements-5914915)
- 2025-02-25 21:07 UTC [Earnings Date] [ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025](https://www.quantisnow.com/insight/chromadex-to-report-fourth-quarter-and-fiscal-year-2024-financial-5908139)
- 2025-02-14 23:19 UTC [SEC Form 4] [SEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-general-counsel-lopez-carlos-5892073)
- 2025-02-14 23:18 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Pamir Ozan](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-pamir-ozan-5892067)
- 2025-02-14 23:17 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Fried Robert N](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-fried-robert-5892063)
- 2025-01-06 13:32 UTC [Conference Announcement] [ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025](https://www.quantisnow.com/insight/chromadex-to-participate-in-the-lytham-partners-2025-investor-healthcare-5833935)
- 2024-12-16 21:00 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-changes-in-registrants-certifying-5814695)
- 2024-12-14 00:12 UTC [SEC Form 4] [Director Jaksch Frank L Jr exercised 50,001 shares at a strike of $3.66 and sold $229,956 worth of shares (37,161 units at $6.19), increasing direct ownership by 6% to 244,179 units (SEC Form 4)](https://www.quantisnow.com/insight/director-jaksch-frank-l-jr-exercised-50001-shares-at-a-5813660)
- 2024-12-04 22:26 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-other-events-5800758)
- 2024-12-03 13:34 UTC [ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category](https://www.quantisnow.com/insight/chromadex-named-to-the-inc-2024-best-in-business-list-5797309)
- 2024-11-25 12:28 UTC [Insider Buy] [Chief Financial Officer Pamir Ozan bought $21,397 worth of shares (2,907 units at $7.36) (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-pamir-ozan-bought-21397-worth-of-shares-5789440)
- 2024-11-21 22:20 UTC [SEC Form 424B3] [SEC Form 424B3 filed by ChromaDex Corporation](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-chromadex-corporation-5787300)
- 2024-11-21 21:01 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-entry-into-a-material-5786630)
- 2024-11-14 13:32 UTC [ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement](https://www.quantisnow.com/insight/chromadexs-patented-nicotinamide-riboside-nr-ingredient-niagen-featured-as-the-5773510)
- 2024-11-08 21:47 UTC [SEC Form 3] [New insider Lopez Carlos Luis claimed ownership of 1,978 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-lopez-carlos-luis-claimed-ownership-of-1978-shares-5763060)
- 2024-11-07 13:32 UTC [ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide](https://www.quantisnow.com/insight/chromadexs-pharmaceutical-grade-niagen-iv-now-accessible-at-over-200-restore-5757936)
- 2024-10-31 20:04 UTC [Earnings Date] [ChromaDex Corporation Reports Third Quarter 2024 Financial Results](https://www.quantisnow.com/insight/chromadex-corporation-reports-third-quarter-2024-financial-results-5746388)
- 2024-10-31 20:01 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-results-of-operations-and-5746354)
- 2024-10-31 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ChromaDex Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-chromadex-corporation-5746341)
- 2024-10-28 12:32 UTC [Earnings Date] [ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024](https://www.quantisnow.com/insight/chromadex-to-report-third-quarter-2024-financial-results-on-thursday-5739522)
- 2024-10-24 12:32 UTC [Earnings Date] [ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024](https://www.quantisnow.com/insight/chromadex-to-report-third-quarter-2024-financial-results-on-thursday-5736487)
- 2024-10-23 21:04 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Pamir Ozan](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-pamir-ozan-5735530)
- 2024-10-23 21:03 UTC [SEC Form 3] [SEC Form 3 filed by new insider Pamir Ozan](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-pamir-ozan-5735527)
- 2024-10-23 12:34 UTC [Conference Announcement] [ChromaDex to Participate in the 17th Annual LD Micro Main Event](https://www.quantisnow.com/insight/chromadex-to-participate-in-the-17th-annual-ld-micro-main-5734624)
- 2024-10-15 12:32 UTC [Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)](https://www.quantisnow.com/insight/yasmeen-nkrumah-elie-phd-global-director-of-external-research-at-chromadex-5724943)
- 2024-10-11 20:00 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-changes-in-registrants-certifying-5723358)
- 2024-09-26 20:12 UTC [Conference Announcement] [ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference](https://www.quantisnow.com/insight/chromadex-to-participate-in-a-fireside-chat-at-the-lytham-5705970)
- 2024-09-20 12:32 UTC [SEC Form 8-K] [ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/chromadex-corporation-filed-sec-form-8-k-leadership-update-financial-statements-5700462)
- 2024-09-20 12:32 UTC [Leadership Update] [ChromaDex Appoints Ozan Pamir as Chief Financial Officer](https://www.quantisnow.com/insight/chromadex-appoints-ozan-pamir-as-chief-financial-officer-5700459)
- 2024-09-09 12:34 UTC [ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions](https://www.quantisnow.com/insight/chromadex-celebrates-25-years-of-innovation-and-pioneering-nad-research-5686835)
- 2024-08-26 23:06 UTC [SEC Form 4] [Director Patrick Kristin exercised 23,000 shares at a strike of $1.67 and sold $82,110 worth of shares (23,000 units at $3.57) (SEC Form 4)](https://www.quantisnow.com/insight/director-patrick-kristin-exercised-23000-shares-at-a-strike-of-5672383)
- 2024-08-23 12:34 UTC [Conference Announcement] [ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024](https://www.quantisnow.com/insight/chromadex-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-5670162)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CDXC
- Earnings history: https://www.quantisnow.com/earnings/CDXC
- Dividend history: https://www.quantisnow.com/dividends/CDXC
- Insider transactions: https://www.quantisnow.com/insiders/CDXC
- Options chain: https://www.quantisnow.com/options/CDXC
- SEC 8-K filings only: https://www.quantisnow.com/company/CDXC/8-k
- RSS and alerts for CDXC: https://www.quantisnow.com/docs/rss-feeds.md